☰

Leon J. Thal, MD - Publications

Affiliations: 
Neuroscience University of California, San Diego, La Jolla, CA 
Area:
http://www.researchprofiles.collexis.com/jad/expert.asp?u_id=27
Website:
http://ucsdnews.ucsd.edu/newsrel/health/thal07.asp
Tree Info Grants Similar researchers PubMed Report error

272 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2011 Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry. 68: 853-61. PMID 21810649 DOI: 10.1001/Archgenpsychiatry.2011.72  0.425
2010 Rapp SR, Legault C, Henderson VW, Brunner RL, Masaki K, Jones B, Absher J, Thal L. Subtypes of mild cognitive impairment in older postmenopausal women: the Women's Health Initiative Memory Study. Alzheimer Disease and Associated Disorders. 24: 248-55. PMID 20473134 DOI: 10.1097/WAD.0b013e3181d715d5  0.354
2010 Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Human Brain Mapping. 31: 786-97. PMID 20143386 DOI: 10.1002/Hbm.20905  0.394
2009 Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Current Alzheimer Research. 6: 144-51. PMID 19355849 DOI: 10.2174/156720509787602852  0.309
2008 Hamilton JM, Salmon DP, Galasko D, Raman R, Emond J, Hansen LA, Masliah E, Thal LJ. Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies. Neuropsychology. 22: 729-37. PMID 18999346 DOI: 10.1037/A0012949  0.633
2008 Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. Jama. 300: 1774-83. PMID 18854539 DOI: 10.1001/Jama.300.15.1774  0.371
2008 van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ, Jack CR, DeCarli C. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. Journal of Neurology. 255: 1302-8. PMID 18825439 DOI: 10.1007/S00415-008-0874-Y  0.509
2008 Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Archives of Neurology. 65: 1031-8. PMID 18695053 DOI: 10.1001/Archneur.65.8.1031  0.388
2008 Fine EM, Delis DC, Wetter SR, Jacobson MW, Jak AJ, McDonald CR, Braga JC, Thal LJ, Salmon DP, Bondi MW. Cognitive discrepancies versus APOE genotype as predictors of cognitive decline in normal-functioning elderly individuals: a longitudinal study. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 16: 366-74. PMID 18448849 DOI: 10.1097/Jgp.0B013E3181629957  0.357
2008 Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Current Alzheimer Research. 5: 73-82. PMID 18288935 DOI: 10.2174/156720508783884602  0.496
2008 Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR, Aisen PS, Thal LJ. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 70: 191-9. PMID 18195264 DOI: 10.1212/01.Wnl.0000287091.57376.65  0.357
2008 Li Y, Grupe A, Rowland C, Holmans P, Segurado R, Abraham R, Jones L, Catanese J, Ross D, Mayo K, Martinez M, Hollingworth P, Goate A, Cairns NJ, Racette BA, ... ... Thal LJ, et al. Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Human Molecular Genetics. 17: 759-67. PMID 18063669 DOI: 10.1093/Hmg/Ddm348  0.36
2008 Delano-Wood L, Houston WS, Emond JA, Marchant NL, Salmon DP, Jeste DV, Thal LJ, Bondi MW. APOE genotype predicts depression in women with Alzheimer's disease: a retrospective study. International Journal of Geriatric Psychiatry. 23: 632-6. PMID 18058831 DOI: 10.1002/Gps.1953  0.342
2008 Jack CR, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiology of Aging. 29: 1285-95. PMID 17452062 DOI: 10.1016/J.Neurobiolaging.2007.03.004  0.397
2008 Lu P, Edland S, Teng E, Tingus K, Thal L, Cummings J. P1-194: Effects of donepezil on the relationship between depression and progression to Alzheimer's disease in patients with mild cognitive impairment Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.782  0.416
2008 Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Alzheimer's Disease Neuroimaging Initiative Neuroimage. 45: 183-189. DOI: 10.1007/978-0-387-72076-0_18  0.443
2007 Thal L, Kuller L, Bowman K, Breitner J, Evans D, Farrer L, Frank R, Khachaturian AS, Khachaturian ZS, Kukull W, Nieto J, Petersen R, Sager M, Scherr P, Bain LJ. The Nevada Vital Aging Initiative: a private-public partnership to study early predictors of dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 3: 62-7. PMID 19595919 DOI: 10.1016/J.Jalz.2006.11.002  0.395
2007 Mickes L, Wixted JT, Fennema-Notestine C, Galasko D, Bondi MW, Thal LJ, Salmon DP. Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease. Neuropsychology. 21: 696-705. PMID 17983283 DOI: 10.1037/0894-4105.21.6.696  0.566
2007 Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA, Reiman EM, Kowall N, Landreth G, Shelanski M, Welsh-Bohmer K, ... ... Thal LJ, et al. The National Alzheimer's Coordinating Center (NACC) database: The uniform data set Alzheimer Disease and Associated Disorders. 21: 249-258. PMID 17804958 DOI: 10.1097/Wad.0B013E318142774E  0.361
2007 Galasko D, Salmon D, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Brooks P, Adonay R, Craig UK, Schellenberg G, Borenstein AR. Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE. Neurology. 68: 1772-81. PMID 17515539 DOI: 10.1212/01.Wnl.0000262028.16738.64  0.563
2007 Borenstein AR, Mortimer JA, Schofield E, Wu Y, Salmon DP, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Craig UL, Schellenberg GD, Galasko DR. Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology. 68: 1764-71. PMID 17515538 DOI: 10.1212/01.Wnl.0000262027.31623.B2  0.51
2007 Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism Neurology. 68: 1356-1363. PMID 17452579 DOI: 10.1212/01.Wnl.0000260060.60870.89  0.385
2007 Wahrle SE, Shah AR, Fagan AM, Smemo S, Kauwe JS, Grupe A, Hinrichs A, Mayo K, Jiang H, Thal LJ, Goate AM, Holtzman DM. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Molecular Neurodegeneration. 2: 7. PMID 17430597 DOI: 10.1186/1750-1326-2-7  0.408
2007 Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A, Jehu L, Segurado R, Stone D, Schadt E, Karnoub M, Nowotny P, Tacey K, Catanese J, Sninsky J, ... ... Thal L, et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Human Molecular Genetics. 16: 865-73. PMID 17317784 DOI: 10.1093/Hmg/Ddm031  0.31
2007 Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 68: 1588-95. PMID 17287448 DOI: 10.1212/01.Wnl.0000258542.58725.4C  0.4
2007 DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, Thal LJ, Jin S, Jack CR, Scheltens P. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Archives of Neurology. 64: 108-15. PMID 17210817 DOI: 10.1001/Archneur.64.1.108  0.459
2007 Rascovsky K, Salmon DP, Hansen LA, Thal LJ, Galasko D. Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. Neuropsychology. 21: 20-30. PMID 17201527 DOI: 10.1037/0894-4105.21.1.20  0.614
2007 Han SD, Houston WS, Jak AJ, Eyler LT, Nagel BJ, Fleisher AS, Brown GG, Corey-Bloom J, Salmon DP, Thal LJ, Bondi MW. Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiology of Aging. 28: 238-47. PMID 16434125 DOI: 10.1016/J.Neurobiolaging.2005.12.013  0.561
2007 Tariot PN, Thal L, Jakimovich L, Schneider L, Cummings J, Raman R, Edland S. P-205: Valproate therapy to attenuate the clinical progression of Alzheimer's disease: Design of the ADCS valproate neuroprotection trial Alzheimer's & Dementia. 3: S163-S164. DOI: 10.1016/J.Jalz.2007.04.110  0.378
2007 Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust WJ, Trojanowski JQ, Shaw LM, Toga AW, Beckett LA, Gamst AC. O1-04-04: The Alzheimer's disease neuroimaging initiative: Progress report Alzheimer's & Dementia. 3: S174-S174. DOI: 10.1016/J.Jalz.2007.04.080  0.386
2006 Beal MF, Bossy-Wetzel E, Finkbeiner S, Fiskum G, Giasson B, Johnson C, Khachaturian ZS, Lee VM, Nicholls D, Reddy H, Reynolds I, Teplow DB, Thal LJ, Trojanowski JQ, Walsh DM, et al. Common threads in neurodegenerative disorders of aging. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 322-6. PMID 19595906 DOI: 10.1016/J.Jalz.2006.08.008  0.443
2006 Grundman M, Petersen RC, Bennett DA, Feldman HH, Salloway S, Visser PJ, Thal LJ, Schenk D, Khachaturian Z, Thies W. Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned? Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 220-33. PMID 19595891 DOI: 10.1016/J.Jalz.2006.04.010  0.508
2006 Yaari R, Fleisher AS, Gamst AC, Bagwell VP, Thal LJ. Utility of the telephone interview for cognitive status for enrollment in clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 104-9. PMID 19595866 DOI: 10.1016/j.jalz.2006.02.004  0.32
2006 Sano M, Zhu CW, Whitehouse PJ, Edland S, Jin S, Ernstrom K, Thomas RG, Thal LJ, Ferris SH. ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly. Alzheimer Disease and Associated Disorders. 20: S191-202. PMID 17135812 DOI: 10.1097/01.Wad.0000213875.63171.87  0.409
2006 Salmon DP, Cummings JL, Jin S, Sano M, Sperling RA, Zamrini E, Petersen RC, Edland SD, Thal LJ, Ferris SH. ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials. Alzheimer Disease and Associated Disorders. 20: S139-46. PMID 17135807 DOI: 10.1097/01.Wad.0000213871.40300.68  0.32
2006 Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Disease and Associated Disorders. 20: S109-23. PMID 17135805 DOI: 10.1097/01.Wad.0000213870.40300.21  0.56
2006 Sano M, Egelko S, Jin S, Cummings J, Clark CM, Pawluczyk S, Thomas RJ, Schittini M, Thal LJ. Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials. Alzheimer Disease and Associated Disorders. 20: 232-41. PMID 17132967 DOI: 10.1097/01.Wad.0000213862.20108.F5  0.49
2006 Thal LJ. Prevention of Alzheimer disease. Alzheimer Disease and Associated Disorders. 20: S97-9. PMID 16917204 DOI: 10.1097/00002093-200607001-00015  0.432
2006 Thal LJ, Kawas C, Galasko D, Salmon DP, Sundsmo MP. Robert Katzman honored. Alzheimer Disease and Associated Disorders. 20: S27-8. PMID 16917190 DOI: 10.1097/00002093-200607001-00001  0.383
2006 Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Praticò D, Griffin S, Schenk D, Siemers E. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Disease and Associated Disorders. 20: 6-15. PMID 16493230 DOI: 10.1097/01.Wad.0000191420.61260.A8  0.598
2006 Webster B, Hansen L, Adame A, Crews L, Torrance M, Thal L, Masliah E. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. Journal of Neuropathology and Experimental Neurology. 65: 142-51. PMID 16462205 DOI: 10.1097/01.Jnen.0000199599.63204.6F  0.476
2006 Elson JL, Herrnstadt C, Preston G, Thal L, Morris CM, Edwardson JA, Beal MF, Turnbull DM, Howell N. Does the mitochondrial genome play a role in the etiology of Alzheimer's disease? Human Genetics. 119: 241-54. PMID 16408223 DOI: 10.1007/S00439-005-0123-8  0.428
2006 Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain : a Journal of Neurology. 129: 729-35. PMID 16401618 DOI: 10.1093/Brain/Awh725  0.676
2006 Smemo S, Nowotny P, Hinrichs AL, Kauwe JS, Cherny S, Erickson K, Myers AJ, Kaleem M, Marlowe L, Gibson AM, Hollingworth P, O'Donovan MC, Morris CM, Holmans P, Lovestone S, ... ... Thal L, et al. Ubiquilin 1 polymorphisms are not associated with late-onset Alzheimer's disease. Annals of Neurology. 59: 21-6. PMID 16278862 DOI: 10.1002/Ana.20673  0.328
2006 Vellas B, Thal L. Prevention trials in the field of Alzheimer disease Neurology. 67: S1. DOI: 10.1212/Wnl.67.9_Suppl_3.S1  0.403
2006 Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Beckett LA. IC-P-104: Imaging biomarkers to monitor treatment effects for Alzheimer's disease trials: The Alzheimer's disease imaging initiative Alzheimer's & Dementia. 2: S694-S694. DOI: 10.1016/J.Jalz.2006.05.2310  0.388
2006 Jack CR, Petersen RC, Grundman M, Ward C, Jin S, Gamst A, Sencakova D, Thal LJ. IC-P-094: Treatment of mild cognitive impairment with vitamin E and donepezil: Correlation between rates of change on MRI and cognitive/behavioral measures Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.2298  0.314
2006 Galasko D, Salmon D, Olichney J, Thal LJ, Gamst A, Silbert L, Kaye J, Borenstein A, Schellenberg G, Brooks P, Adonay R, Craig U. P3-147: The prevalence of dementia among elderly chamorros on guam and lack of association with the APO e4 allele Alzheimer's & Dementia. 2: S417-S417. DOI: 10.1016/J.Jalz.2006.05.1415  0.53
2006 Emond JA, Jin S, Bochenek J, Thal LJ, Petersen RC, Sano M, Edland SD. P3-120: Predictors of dropout in clinical trials of subjects with mild cognitive impairment (MCI) Alzheimer's & Dementia. 2: S409-S409. DOI: 10.1016/J.Jalz.2006.05.1388  0.345
2006 Grupe A, Li Y, Rowland C, Abraham R, Hollingworth P, Morgan A, Jehu L, Stone D, Schadt E, Karnoub M, Nowotny P, Tacey K, Catanese J, Sninsky J, Rubinsztein D, ... ... Thal L, et al. O2-02-05: Novel candidate genes for late-onset Alzheimer's disease from a large scale association study of 20K functional variants Alzheimer's & Dementia. 2: S33-S33. DOI: 10.1016/J.Jalz.2006.05.115  0.341
2006 Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Beckett LA. P2-254: Imaging biomarkers to monitor treatment effects for Alzheimer's disease trials: The Alzheimer's disease imaging initiative Alzheimer's & Dementia. 2: S311-S311. DOI: 10.1016/J.Jalz.2006.05.1093  0.395
2006 Fleisher AS, Sowell B, Taylor C, Gamst A, Petersen RC, Thal LJ. P2-171: Clinical predictors of progression to Alzheimer’s disease in amnestic mild cognitive impairment Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.1009  0.382
2005 Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 1: 55-66. PMID 17476317 DOI: 10.1016/J.Jalz.2005.06.003  0.494
2005 Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). Cns Drug Reviews. 11: 353-68. PMID 16614735 DOI: 10.1111/J.1527-3458.2005.Tb00053.X  0.314
2005 Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clinics of North America. 15: 869-77, xi-xii. PMID 16443497 DOI: 10.1016/J.Nic.2005.09.008  0.47
2005 Fleisher AS, Houston WS, Eyler LT, Frye S, Jenkins C, Thal LJ, Bondi MW. Identification of Alzheimer disease risk by functional magnetic resonance imaging. Archives of Neurology. 62: 1881-8. PMID 16344346 DOI: 10.1001/Archneur.62.12.1881  0.425
2005 Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: A randomized, controlled trial American Journal of Geriatric Psychiatry. 13: 942-949. PMID 16286437 DOI: 10.1097/00019442-200511000-00004  0.369
2005 Olichney JM, Murphy C, Hofstetter CR, Foster K, Hansen LA, Thal LJ, Katzman R. Anosmia is very common in the Lewy body variant of Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 76: 1342-7. PMID 16170073 DOI: 10.1136/jnnp.2003.032003  0.645
2005 Wu CK, Thal L, Pizzo D, Hansen L, Masliah E, Geula C. Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer's disease Experimental Neurology. 195: 484-496. PMID 16085017 DOI: 10.1016/J.Expneurol.2005.06.020  0.367
2005 Palmer BW, Dunn LB, Appelbaum PS, Mudaliar S, Thal L, Henry R, Golshan S, Jeste DV. Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. Archives of General Psychiatry. 62: 726-33. PMID 15997013 DOI: 10.1001/Archpsyc.62.7.726  0.358
2005 Li Y, Rowland C, Tacey K, Catanese J, Sninsky J, Hardy J, Powell J, Lovestone S, Morris JC, Thal L, Goate A, Owen M, Williams J, Grupe A. The BDNF Val66Met polymorphism is not associated with late onset Alzheimer's disease in three case-control samples. Molecular Psychiatry. 10: 809-10. PMID 15970929 DOI: 10.1038/Sj.Mp.4001702  0.399
2005 Fleisher A, Grundman M, Jack CR, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Archives of Neurology. 62: 953-7. PMID 15956166 DOI: 10.1001/Archneur.62.6.953  0.364
2005 Nowotny P, Hinrichs AL, Smemo S, Kauwe JS, Maxwell T, Holmans P, Hamshere M, Turic D, Jehu L, Hollingworth P, Moore P, Bryden L, Myers A, Doil LM, Tacey KM, ... ... Thal L, et al. Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 136: 62-8. PMID 15858813 DOI: 10.1002/Ajmg.B.30186  0.319
2005 Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nature Medicine. 11: 551-5. PMID 15852017 DOI: 10.1038/Nm1239  0.438
2005 Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. The New England Journal of Medicine. 352: 2379-88. PMID 15829527 DOI: 10.1056/Nejmoa050151  0.606
2005 Sabbagh MN, Tyas SL, Emery SC, Hansen LA, Alford MF, Reid RT, Tiraboschi P, Thal LJ. Smoking affects the phenotype of Alzheimer disease. Neurology. 64: 1301-3. PMID 15824373 DOI: 10.1212/01.WNL.0000156912.54593.65  0.337
2005 Tractenberg RE, Weiner MF, Cummings JL, Patterson MB, Thal LJ. Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach. The Journal of Neuropsychiatry and Clinical Neurosciences. 17: 51-60. PMID 15746483 DOI: 10.1176/Jnp.17.1.51  0.433
2005 Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30: 1204-15. PMID 15742005 DOI: 10.1038/sj.npp.1300690  0.514
2005 Li Y, Hollingworth P, Moore P, Foy C, Archer N, Powell J, Nowotny P, Holmans P, O'Donovan M, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Lau K, ... ... Thal L, et al. Genetic association of the APP binding protein 2 gene (APBB2) with late onset Alzheimer disease. Human Mutation. 25: 270-7. PMID 15714520 DOI: 10.1002/Humu.20138  0.405
2005 Ho GJ, Hashimoto M, Adame A, Izu M, Alford MF, Thal LJ, Hansen LA, Masliah E. Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role. Neurobiology of Aging. 26: 625-35. PMID 15708437 DOI: 10.1016/J.Neurobiolaging.2004.06.016  0.495
2005 Thal LJ, Thomas RG, Grundman M, Bennett DA, Doody RS, Ferris SH, Galasko DR, Jin S, Levey AI, Petersen RC. [O2-01-01]: Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis Alzheimer's & Dementia. 1: S93-S94. DOI: 10.1016/J.Jalz.2005.06.326  0.557
2005 Thal L. Alzheimer's Disease Cooperative Study (ADCS): Overview Research and Practice in Alzheimer's Disease. 10: 25-33.  0.331
2004 Thal LJ. The Alzheimer's Disease Cooperative Study in 2004. Alzheimer Disease and Associated Disorders. 18: 183-5. PMID 15592126  0.332
2004 Li Y, Nowotny P, Holmans P, Smemo S, Kauwe JS, Hinrichs AL, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Schrodi S, Leong D, Gogic G, Chan J, ... ... Thal L, et al. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proceedings of the National Academy of Sciences of the United States of America. 101: 15688-93. PMID 15507493 DOI: 10.1073/Pnas.0403535101  0.394
2004 Hamilton JM, Salmon DP, Galasko D, Delis DC, Hansen LA, Masliah E, Thomas RG, Thal LJ. A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease. Journal of the International Neuropsychological Society : Jins. 10: 689-97. PMID 15327716 DOI: 10.1017/S1355617704105043  0.611
2004 Li Y, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Schrodi S, Leong D, Lau K, Catanese J, Sninsky J, Nowotny P, Holmans P, Hardy J, Powell J, ... ... Thal L, et al. Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study. Neuroscience Letters. 366: 268-71. PMID 15288432 DOI: 10.1016/J.Neulet.2004.05.047  0.336
2004 Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study Journal of the American Medical Association. 291: 2947-2958. PMID 15213206 DOI: 10.1001/jama.291.24.2947  0.325
2004 Licastro F, Chiappelli M, Thal LJ, Masliah E. alpha-1-Antichymotrypsin polymorphism in the gene promoter region affects survival and synapsis loss in Alzheimer's disease. Archives of Gerontology and Geriatrics. Supplement. 243-51. PMID 15207421 DOI: 10.1016/J.Archger.2004.04.034  0.457
2004 Brandon EP, Mellott T, Pizzo DP, Coufal N, D'Amour KA, Gobeske K, Lortie M, López-Coviella I, Berse B, Thal LJ, Gage FH, Blusztajn JK. Choline transporter 1 maintains cholinergic function in choline acetyltransferase haploinsufficiency. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 5459-66. PMID 15201317 DOI: 10.1523/Jneurosci.1106-04.2004  0.679
2004 Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology. 62: 1984-9. PMID 15184601 DOI: 10.1212/01.Wnl.0000129697.01779.0A  0.643
2004 Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. 62: 1977-83. PMID 15184600 DOI: 10.1212/01.Wnl.0000128091.92139.0F  0.625
2004 Swanberg MM, Tractenberg RE, Mohs R, Thal LJ, Cummings JL. Executive dysfunction in Alzheimer disease. Archives of Neurology. 61: 556-60. PMID 15096405 DOI: 10.1001/Archneur.61.4.556  0.4
2004 Tiraboschi P, Sabbagh MN, Hansen LA, Salmon DP, Merdes A, Gamst A, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Alzheimer disease without neocortical neurofibrillary tangles: "a second look". Neurology. 62: 1141-7. PMID 15079014 DOI: 10.1212/01.Wnl.0000118212.41542.E7  0.654
2004 Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, ... ... Thal LJ, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Archives of Neurology. 61: 59-66. PMID 14732621 DOI: 10.1001/Archneur.61.1.59  0.626
2004 Li Y, Hollingworth P, Moore P, Foy C, Archer N, Nowotny P, Holmans P, Smemo S, Tacey K, Doil L, Luchene Rv, Lau K, Catanese J, Garcia V, Rowland C, ... ... Thal L, et al. P4-122 Genetic association of an APP binding protein gene with late onset Alzheimer's disease Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)81680-4  0.373
2004 Doil L, Tacey K, Nowotny P, Luchene Rv, Li Y, Holmans P, Smemo S, Garcia V, Rowland C, Leong D, Gogic G, Cravchik A, Ross D, Lau K, Catanese J, ... ... Thal L, et al. P4-110 A systematic scan of chromosome 10 single nucleotide polymorphisms identifies novel candidate genes showing strong association to Alzheimer's disease Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)81668-3  0.352
2004 Li Y, Nowotny P, Holmans P, Smemo S, Kawe K, Tacey K, Doil L, Luchene Rv, Garcia V, Rowland C, Schrodi S, Leong D, Chan J, Lau K, Chang S, ... ... Thal L, et al. P4-046 Association of late onset Alzheimer's disease with genetic variation in multiple members of a gene family involved in neuronal apoptosis Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)81604-X  0.342
2004 Rascovsky K, Salmon DP, Galasko D, Hansen LA, Thal LJ. P3-344 Differential contributions of cognitive and behavioral deficits to functional impairment in FTD and AD Neurobiology of Aging. 25: S453. DOI: 10.1016/S0197-4580(04)81493-3  0.554
2004 Wu C, Stopa E, Geula C, Thal L. P3-250 Neurofibrillary degeneration is linked with an apoptotic signal - fas-associated death domain in the basal forebrain cholinergic neurons of Alzheimer's disease Neurobiology of Aging. 25: S425-S426. DOI: 10.1016/S0197-4580(04)81400-3  0.358
2004 Fennema-Notestine C, Archibald SL, Gamst AC, Thal LJ, Jernigan TL. P3-091 Regional distribution of white matter changes in Alzheimer's disease Neurobiology of Aging. 25: S379-S380. DOI: 10.1016/S0197-4580(04)81243-0  0.473
2004 Sabbagh MN, Tyas SL, Emery SC, Hansen LA, Alford MF, Reid RT, Tiraboschi P, Thal LJ. P2-265 Smoking affects the phenotype of Alzheimer's disease Neurobiology of Aging. 25: S307. DOI: 10.1016/S0197-4580(04)81010-8  0.356
2004 Tariot PN, Thal L, Jakimovich L, Thomas R, Raman R. P1-322 A multicenter, randomized, double-blind, placebo-controlled trial of valproate for agitation associated with dementia Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)80635-3  0.314
2004 Thal L. S5-03-02 Prevention trials in Alzheimer's disease: design issues Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)80310-5  0.381
2004 Hamilton JM, Salmon DP, Galasko D, Hansen LA, Thal LJ. O4-06-05 Differential prediction of global cognitive decline in autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease Neurobiology of Aging. 25: S86. DOI: 10.1016/S0197-4580(04)80292-6  0.577
2003 Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology. 61: 1498-502. PMID 14663031 DOI: 10.1212/01.Wnl.0000096376.03678.C1  0.47
2003 Caligiuri MP, Peavy G, Salmon DP, Galasko DR, Thal LJ. Neuromotor abnormalities and risk for psychosis in Alzheimer's disease. Neurology. 61: 954-8. PMID 14557567 DOI: 10.1212/01.Wnl.0000086823.08213.De  0.541
2003 Grundman M, Jack CR, Petersen RC, Kim HT, Taylor C, Datvian M, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Darvesh S, Yaffe K, Kaye J, Ferris SH, Thomas RG, ... Thal LJ, et al. Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment. Journal of Molecular Neuroscience : Mn. 20: 241-8. PMID 14501003 DOI: 10.1385/Jmn:20:3:241  0.429
2003 Bondi MW, Houston WS, Salmon DP, Corey-Bloom J, Katzman R, Thal LJ, Delis DC. Neuropsychological deficits associated with Alzheimer's disease in the very-old: discrepancies in raw vs. standardized scores. Journal of the International Neuropsychological Society : Jins. 9: 783-95. PMID 12901784 DOI: 10.1017/S1355617703950119  0.744
2003 Masliah E, Alford M, Adame A, Rockenstein E, Galasko D, Salmon D, Hansen LA, Thal LJ. Abeta1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. Neurology. 61: 206-11. PMID 12874400 DOI: 10.1212/01.Wnl.0000073987.79060.4B  0.313
2003 Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, Girones X, Henry TL, Matsubara E, Zambon D, Wolozin B, Sano M, Cruz-Sanchez FF, Thal LJ, Petanceska SS, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 61: 199-205. PMID 12874399 DOI: 10.1212/01.Wnl.0000070182.02537.84  0.417
2003 Thal LJ. Therapeutics and mild cognitive impairment: current status and future directions. Alzheimer Disease and Associated Disorders. 17: S69-71. PMID 12813215 DOI: 10.1097/00002093-200304002-00012  0.302
2003 Kennedy BP, Ziegler MG, Alford M, Hansen LA, Thal LJ, Masliah E. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 110: 789-801. PMID 12811639 DOI: 10.1007/S00702-003-0828-6  0.33
2003 Tractenberg RE, Weiner MF, Patterson MB, Teri L, Thal LJ. Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology. 16: 94-9. PMID 12801159 DOI: 10.1177/0891988703016002006  0.329
2003 Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Jama. 289: 2819-26. PMID 12783912 DOI: 10.1001/Jama.289.21.2819  0.477
2003 Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, Thal LJ, Corey-Bloom J. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 60: 1586-90. PMID 12771246 DOI: 10.1212/01.Wnl.0000065889.42856.F2  0.678
2003 Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Jama. 289: 2651-62. PMID 12771112 DOI: 10.1001/Jama.289.20.2651  0.324
2003 Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, Heidebrink J, Hake A, Ho G, Schultz AN, Schafer K, Houston W, Thomas R, Thal LJ. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sciences. 73: 539-53. PMID 12770610 DOI: 10.1016/S0024-3205(03)00320-5  0.366
2003 Thal LJ, Thomas RG, Mulnard R, Sano M, Grundman M, Schneider L. Estrogen levels do not correlate with improvement in cognition. Archives of Neurology. 60: 209-12. PMID 12580705 DOI: 10.1001/Archneur.60.2.209  0.345
2003 Palmer BW, Bondi MW, Twamley EW, Thal L, Golshan S, Jeste DV. Are late-onset schizophrenia spectrum disorders neurodegenerative conditions? Annual rates of change on two dementia measures. The Journal of Neuropsychiatry and Clinical Neurosciences. 15: 45-52. PMID 12556570 DOI: 10.1176/Jnp.15.1.45  0.423
2003 Brandon EP, Lin W, D'Amour KA, Pizzo DP, Dominguez B, Sugiura Y, Thode S, Ko CP, Thal LJ, Gage FH, Lee KF. Aberrant patterning of neuromuscular synapses in choline acetyltransferase-deficient mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 539-49. PMID 12533614 DOI: 10.1523/Jneurosci.23-02-00539.2003  0.663
2003 Aisen PS, Berg JD, Craft S, Peskind ER, Sano M, Teri L, Mulnard RA, Thomas RG, Thal LJ. Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition. Psychoneuroendocrinology. 28: 113-20. PMID 12445840 DOI: 10.1016/S0306-4530(02)00015-X  0.343
2002 Tuszynski MH, U HS, Alksne J, Bakay RA, Pay MM, Merrill D, Thal LJ. Growth factor gene therapy for Alzheimer disease. Neurosurgical Focus. 13: e5. PMID 15769074 DOI: 10.3171/Foc.2002.13.5.6  0.335
2002 Lange KL, Bondi MW, Salmon DP, Galasko D, Delis DC, Thomas RG, Thal LJ. Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. Journal of the International Neuropsychological Society : Jins. 8: 943-55. PMID 12405546 DOI: 10.1017/S1355617702870096  0.579
2002 Ho GJ, Hansen LA, Alford MF, Foster K, Salmon DP, Galasko D, Thal LJ, Masliah E. Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. Neuroreport. 13: 1825-8. PMID 12395133 DOI: 10.1097/00001756-200210070-00028  0.638
2002 Salmon DP, Thomas RG, Pay MM, Booth A, Hofstetter CR, Thal LJ, Katzman R. Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals. Neurology. 59: 1022-8. PMID 12370456 DOI: 10.1016/0166-2236(86)90165-7  0.618
2002 Tiraboschi P, Hansen LA, Alford M, Merdes A, Masliah E, Thal LJ, Corey-Bloom J. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Archives of General Psychiatry. 59: 946-51. PMID 12365882 DOI: 10.1001/Archpsyc.59.10.946  0.694
2002 Olichney JM, Morris SK, Ochoa C, Salmon DP, Thal LJ, Kutas M, Iragui VJ. Abnormal verbal event related potentials in mild cognitive impairment and incipient Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 73: 377-84. PMID 12235303 DOI: 10.1136/jnnp.73.4.377  0.364
2002 Grundman M, Sencakova D, Jack CR, Petersen RC, Kim HT, Schultz A, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Thomas RG, Thal LJ. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. Journal of Molecular Neuroscience : Mn. 19: 23-7. PMID 12212787 DOI: 10.1007/S12031-002-0006-6  0.46
2002 Tuszynski MH, Thal L, U HS, Pay MM, Blesch A, Conner J, Vahlsing HL. Nerve growth factor gene therapy for Alzheimer's disease. Journal of Molecular Neuroscience : Mn. 19: 207. PMID 12212782 DOI: 10.1007/S12031-002-0034-2  0.403
2002 Tractenberg RE, Gamst A, Thomas RG, Patterson M, Schneider LS, Thal LJ. Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer's disease. The Journal of Neuropsychiatry and Clinical Neurosciences. 14: 303-10. PMID 12154155 DOI: 10.1176/Jnp.14.3.303  0.379
2002 Pappolla MA, Smith MA, Bryant-Thomas T, Bazan N, Petanceska S, Perry G, Thal LJ, Sano M, Refolo LM. Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. Free Radical Biology & Medicine. 33: 173-81. PMID 12106813 DOI: 10.1016/S0891-5849(02)00841-9  0.415
2002 Rascovsky K, Salmon DP, Ho GJ, Galasko D, Peavy GM, Hansen LA, Thal LJ. Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD. Neurology. 58: 1801-8. PMID 12084880 DOI: 10.1212/Wnl.58.12.1801  0.612
2002 Weiner MF, Tractenberg RE, Sano M, Logsdon R, Teri L, Galasko D, Gamst A, Thomas R, Thal LJ. No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients. Journal of Geriatric Psychiatry and Neurology. 15: 95-8. PMID 12083600 DOI: 10.1177/089198870201500208  0.552
2002 Tractenberg RE, Weiner MF, Patterson MB, Gamst A, Thal LJ. Emergent psychopathology in Alzheimer's disease patients over 12 months associated with functional, not cognitive, changes. Journal of Geriatric Psychiatry and Neurology. 15: 110-7. PMID 12083593 DOI: 10.1177/089198870201500210  0.4
2002 Grundman M, Farlow M, Peavy G, Kim HT, Capparelli E, Schultz AN, Salmon DP, Ferris SH, Mobs R, Thomas RG, Schafer K, Campbell K, Hake AM, Schoos B, Thal LJ, et al. A phase I study of AIT-082 in healthy elderly volunteers. Journal of Molecular Neuroscience : Mn. 18: 283-93. PMID 12059047 DOI: 10.1385/Jmn:18:3:283  0.31
2002 Tractenberg RE, Weiner MF, Thal LJ. Estimating the prevalence of agitation in community-dwelling persons with Alzheimer's disease. The Journal of Neuropsychiatry and Clinical Neurosciences. 14: 11-8. PMID 11884649 DOI: 10.1176/Jnp.14.1.11  0.418
2002 Galasko D, Salmon DP, Craig UK, Thal LJ, Schellenberg G, Wiederholt W. Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997-2000. Neurology. 58: 90-7. PMID 11781411 DOI: 10.1212/Wnl.58.1.90  0.526
2002 Weiner MF, Tractenberg RE, Jin S, Gamst A, Thomas RG, Koss E, Thal LJ. Assessing Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory: scoring and clinical implications. Journal of Psychiatric Research. 36: 19-25. PMID 11755457 DOI: 10.1016/S0022-3956(01)00047-4  0.427
2001 Xia Y, Saitoh T, Uéda K, Tanaka S, Chen X, Hashimoto M, Hsu L, Conrad C, Sundsmo M, Yoshimoto M, Thal L, Katzman R, Masliah E. Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms. Journal of Alzheimer's Disease : Jad. 3: 485-494. PMID 12214035 DOI: 10.3233/Jad-2001-3508  0.528
2001 Masliah E, Alford M, Galasko D, Salmon D, Hansen LA, Good PF, Perl DP, Thal L. Cholinergic deficits in the brains of patients with parkinsonism-dementia complex of Guam. Neuroreport. 12: 3901-3. PMID 11742207 DOI: 10.1097/00001756-200112210-00009  0.582
2001 Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Archives of Neurology. 58: 1985-92. PMID 11735772 DOI: 10.1001/Archneur.58.12.1985  0.449
2001 Sabbagh MN, Reid RT, Hansen LA, Alford M, Thal LJ. Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies. Journal of Neural Transmission (Vienna, Austria : 1996). 108: 1149-57. PMID 11725817 DOI: 10.1007/s007020170004  0.495
2001 Reid RT, Sabbagh MN, Thal LJ. Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 108: 1043-50. PMID 11716140 DOI: 10.1007/s007020170023  0.416
2001 Tractenberg RE, Gamst A, Weiner MF, Koss E, Thomas RG, Teri L, Thal L. Frequency of behavioral symptoms characterizes agitation in Alzheimer's disease International Journal of Geriatric Psychiatry. 16: 886-891. PMID 11571769 DOI: 10.1002/Gps.441  0.392
2001 Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 56: 1154-66. PMID 11342679 DOI: 10.1212/Wnl.56.9.1154  0.371
2000 Sabbagh MN, Galasko D, Koo E, Thal LJ. Amyloid-beta and treatment opportunities for Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 2: 231-59. PMID 12214087 DOI: 10.3233/Jad-2000-23-405  0.566
2000 Paulsen JS, Ready RE, Stout JC, Salmon DP, Thal LJ, Grant I, Jeste DV. Neurobehaviors and psychotic symptoms in Alzheimer's disease. Journal of the International Neuropsychological Society : Jins. 6: 815-20. PMID 11105471 DOI: 10.1017/S1355617700677081  0.42
2000 Tiraboschi P, Hansen LA, Alford M, Masliah E, Thal LJ, Corey-Bloom J. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology. 55: 1278-83. PMID 11087768 DOI: 10.1212/Wnl.55.9.1278  0.652
2000 Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, ... ... Thal LJ, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 55: 1271-8. PMID 11087767 DOI: 10.1212/Wnl.55.9.1271  0.387
2000 Tractenberg RE, Jin S, Patterson M, Schneider LS, Gamst A, Thomas RG, Thal LJ. Qualifying change: a method for defining clinically meaningful outcomes of change score computation. Journal of the American Geriatrics Society. 48: 1478-82. PMID 11083327 DOI: 10.1111/Jgs.2000.48.11.1478  0.371
2000 Tractenberg RE, Patterson M, Weiner MF, Teri L, Grundman M, Thomas RG, Thal LJ. Prevalence of symptoms on the CERAD behavior rating scale for dementia in normal elderly subjects and Alzheimer's disease patients. The Journal of Neuropsychiatry and Clinical Neurosciences. 12: 472-9. PMID 11083164 DOI: 10.1176/Jnp.12.4.472  0.453
2000 Grundman M, Thal LJ. Treatment of Alzheimer's disease: rationale and strategies. Neurologic Clinics. 18: 807-28. PMID 11072262 DOI: 10.1016/S0733-8619(05)70227-9  0.346
2000 Lee JH, Olichney JM, Hansen LA, Hofstetter CR, Thal LJ. Small concomitant vascular lesions do not influence rates of cognitive decline in patients with Alzheimer disease. Archives of Neurology. 57: 1474-9. PMID 11030800 DOI: 10.1001/Archneur.57.10.1474  0.508
2000 Rei RT, Sabbagh MN, Corey-Bloom J, Tiraboschi P, Thal LJ. Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease. Neurobiology of Aging. 21: 741-6. PMID 11016544 DOI: 10.1016/S0197-4580(00)00168-8  0.653
2000 Thal LJ, Calvani M, Amato A, Carta A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology. 55: 805-10. PMID 10994000 DOI: 10.1212/Wnl.55.6.805  0.472
2000 Thal LJ. Trials to slow progression and prevent disease onset. Journal of Neural Transmission. Supplementum. 59: 243-9. PMID 10961435  0.301
2000 Olichney JM, Hansen LA, Hofstetter CR, Lee JH, Katzman R, Thal LJ. Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. Archives of Neurology. 57: 869-74. PMID 10867785 DOI: 10.1001/Archneur.57.6.869  0.633
2000 Thal LJ. Anti-inflammatory drugs and Alzheimer's disease. Neurobiology of Aging. 21: 449-50; discussion 4. PMID 10858593 DOI: 10.1016/S0197-4580(00)00139-1  0.335
2000 Thomas RG, Berg JD, Sano M, Thal L. Analysis of longitudinal data in an Alzheimer's disease clinical trial. Statistics in Medicine. 19: 1433-40. PMID 10844708 DOI: 10.1002/(Sici)1097-0258(20000615/30)19:11/12<1433::Aid-Sim435>3.0.Co;2-F  0.474
2000 Bayley PJ, Salmon DP, Bondi MW, Bui BK, Olichney J, Delis DC, Thomas RG, Thal LJ. Comparison of the serial position effect in very mild Alzheimer's disease, mild Alzheimer's disease, and amnesia associated with electroconvulsive therapy. Journal of the International Neuropsychological Society : Jins. 6: 290-8. PMID 10824501 DOI: 10.1017/S1355617700633040  0.448
2000 Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 54: 1965-71. PMID 10822438 DOI: 10.1212/Wnl.54.10.1965  0.564
2000 Olichney JM, Hansen LA, Lee JH, Hofstetter CR, Katzman R, Thal LJ. Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and vascular lesions in Alzheimer's disease. Annals of the New York Academy of Sciences. 903: 138-43. PMID 10818499 DOI: 10.1111/J.1749-6632.2000.Tb06360.X  0.631
2000 Pappas BA, Bayley PJ, Bui BK, Hansen LA, Thal LJ. Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients. Neurobiology of Aging. 21: 11-7. PMID 10794843 DOI: 10.1016/S0197-4580(00)00090-7  0.393
2000 Weiner MF, Tractenberg R, Teri L, Logsdon R, Thomas RG, Gamst A, Thal LJ. Quantifying behavioral disturbance in Alzheimer's disease patients. Journal of Psychiatric Research. 34: 163-7. PMID 10758259 DOI: 10.1016/S0022-3956(99)00042-4  0.383
2000 Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. Diagnostic accuracy of dementia with Lewy bodies. Archives of Neurology. 57: 347-51. PMID 10714660 DOI: 10.1001/Archneur.57.3.347  0.687
2000 Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. Jama. 283: 1007-15. PMID 10697060 DOI: 10.1001/Jama.283.8.1007  0.344
2000 Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 54: 588-93. PMID 10680787 DOI: 10.1212/WNL.54.3.588  0.331
2000 Thal LJ, Forrest M, Loft H, Mengel H. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group. Neurology. 54: 421-6. PMID 10668706 DOI: 10.1212/WNL.54.2.421  0.462
2000 Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thal LJ, Corey-Bloom J. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 54: 407-11. PMID 10668703 DOI: 10.1212/Wnl.54.2.407  0.644
2000 Corey-Bloom J, Tiraboschi P, Hansen LA, Alford M, Schoos B, Sabbagh MN, Masliah E, Thal LJ. E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease. Neurology. 54: 403-6. PMID 10668702 DOI: 10.1212/Wnl.54.2.403  0.62
2000 Licastro F, Masliah E, Pedrini S, Thal LJ. Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer's disease: effects of gender and apolipoprotein E genotype. Dementia and Geriatric Cognitive Disorders. 11: 25-8. PMID 10629358 DOI: 10.1159/000017209  0.431
2000 Thal LJ. Overview of Alzheimer's disease therapeutics Neurobiology of Aging. 21: 212. DOI: 10.1016/S0197-4580(00)83283-2  0.437
2000 Olichney JM, Ochoa C, Morris SK, Salmon DP, Thal LJ, Kutas M, Iragui VJ. Reduced word repetition effects in the event-related potentials of patients with mild cognitive impairment and incipient Alzheimer's disease Neurobiology of Aging. 21: 200. DOI: 10.1016/S0197-4580(00)82242-3  0.417
2000 Sabbagh MN, Galasko D, Koo E, Thal LJ. Amyloid-β and treatment opportunities for Alzheimer's disease Journal of Alzheimer's Disease. 2: 231-259.  0.483
1999 Sabbagh MN, Corey-Bloom J, Tiraboschi P, Thomas R, Masliah E, Thal LJ. Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease. Archives of Neurology. 56: 1458-61. PMID 10593300 DOI: 10.1001/Archneur.56.12.1458  0.652
1999 Logsdon RG, Teri L, Weiner MF, Gibbons LE, Raskind M, Peskind E, Grundman M, Koss E, Thomas RG, Thal LJ. Assessment of agitation in Alzheimer's disease: the agitated behavior in dementia scale. Alzheimer's Disease Cooperative Study. Journal of the American Geriatrics Society. 47: 1354-8. PMID 10573447 DOI: 10.1111/J.1532-5415.1999.Tb07439.X  0.462
1999 Kawas CH, Clark CM, Farlow MR, Knopman DS, Marson D, Morris JC, Thal LJ, Whitehouse PJ. Clinical trials in Alzheimer disease: debate on the use of placebo controls. Alzheimer Disease and Associated Disorders. 13: 124-9. PMID 10485569 DOI: 10.1097/00002093-199907000-00002  0.43
1999 Bondi MW, Salmon DP, Galasko D, Thomas RG, Thal LJ. Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychology and Aging. 14: 295-303. PMID 10403716 DOI: 10.1037//0882-7974.14.2.295  0.613
1999 Hohl U, Grundman M, Salmon DP, Thomas RG, Thal LJ. Mini-Mental State Examination and Mattis Dementia Rating Scale performance differs in Hispanic and non-Hispanic Alzheimer's disease patients. Journal of the International Neuropsychological Society : Jins. 5: 301-7. PMID 10349293 DOI: 10.1017/S1355617799544019  0.44
1999 Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 52: 1146-52. PMID 10214735 DOI: 10.1212/Wnl.52.6.1146  0.434
1999 Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, Sano M. Nursing home placement is related to dementia progression: experience from a clinical trial. Alzheimer's Disease Cooperative Study. Neurology. 52: 714-8. PMID 10078715 DOI: 10.1212/Wnl.52.4.714  0.35
1999 Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U, Thal LJ. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology. 52: 700-8. PMID 10078713 DOI: 10.1212/Wnl.52.4.700  0.35
1999 Paulsen JS, Turner BM, Statler-Cowen T, Romero R, Salmon DP, Thal L, Jeste DV. The nature of the naming deficit in Alzheimer's disease suggests patients at-risk for psychosis Archives of Clinical Neuropsychology. 14: 139-139. DOI: 10.1093/arclin/14.1.139a  0.414
1999 Paulsen JS, Turner BM, Diekman A, Romero R, Salmon DP, Thal L, Jeste DV. Clock drawing and psychosis in Alzheimer's disease Archives of Clinical Neuropsychology. 14: 139-139. DOI: 10.1093/arclin/14.1.139  0.435
1998 Imbimbo BP, Lucca U, Lucchelli F, Alberoni M, Thal LJ. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders. 12: 313-22. PMID 9876959 DOI: 10.1097/00002093-199812000-00011  0.33
1998 Whitehouse PJ, Kittner B, Roessner M, Rossor M, Sano M, Thal L, Winblad B. Clinical trial designs for demonstrating disease-course-altering effects in dementia. Alzheimer Disease and Associated Disorders. 12: 281-94. PMID 9876956 DOI: 10.1097/00002093-199812000-00007  0.474
1998 Weiner MF, Koss E, Patterson M, Jin S, Teri L, Thomas R, Thal LJ, Whitehouse P. A comparison of the Cohen-Mansfield agitation inventory with the CERAD behavioral rating scale for dementia in community-dwelling persons with Alzheimer's disease. Journal of Psychiatric Research. 32: 347-51. PMID 9844950 DOI: 10.1016/S0022-3956(98)00027-2  0.42
1998 Sabbagh MN, Reid RT, Corey-Bloom J, Rao TS, Hansen LA, Alford M, Masliah E, Adem A, Lloyd GK, Thal LJ. Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 105: 709-17. PMID 9826113 DOI: 10.1007/S007020050090  0.601
1998 Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, Thal LJ. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology. 51: 351-7. PMID 9710002 DOI: 10.1212/Wnl.51.2.351  0.696
1998 Grundman M, Corey-Bloom J, Thal LJ. Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. Journal of Neural Transmission. Supplementum. 53: 255-75. PMID 9700663  0.587
1998 Conrad C, Amano N, Andreadis A, Xia Y, Namekataf K, Oyama F, Ikeda K, Wakabayashi K, Takahashi H, Thal LJ, Katzman R, Shackelford DA, Matsushita M, Masliah E, Sawa A. Differences in a dinucleotide repeat polymorphism in the tau gene between Caucasian and Japanese populations: implication for progressive supranuclear palsy. Neuroscience Letters. 250: 135-7. PMID 9697937 DOI: 10.1016/S0304-3940(98)00417-0  0.514
1998 Winkler J, Thal LJ, Gage FH, Fisher LJ. Cholinergic strategies for Alzheimer's disease. Journal of Molecular Medicine (Berlin, Germany). 76: 555-67. PMID 9694432 DOI: 10.1007/s001090050250  0.406
1998 Connor DJ, Salmon DP, Sandy TJ, Galasko D, Hansen LA, Thal LJ. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Archives of Neurology. 55: 994-1000. PMID 9678318 DOI: 10.1001/Archneur.55.7.994  0.645
1998 Hsu LJ, Mallory M, Xia Y, Veinbergs I, Hashimoto M, Yoshimoto M, Thal LJ, Saitoh T, Masliah E. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. Journal of Neurochemistry. 71: 338-44. PMID 9648883 DOI: 10.1046/J.1471-4159.1998.71010338.X  0.365
1998 Tanaka S, Chen X, Xia Y, Kang DE, Matoh N, Sundsmo M, Thomas RG, Katzman R, Thal LJ, Trojanowski JQ, Saitoh T, Ueda K, Masliah E. Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease. Neurology. 50: 1556-62. PMID 9633694 DOI: 10.1212/Wnl.50.6.1556  0.695
1998 Ellis RJ, Jan K, Kawas C, Koller WC, Lyons KE, Jeste DV, Hansen LA, Thal LJ. Diagnostic validity of the dementia questionnaire for Alzheimer disease. Archives of Neurology. 55: 360-5. PMID 9520010 DOI: 10.1001/Archneur.55.3.360  0.439
1998 JIN S, THOMAS R, GALASKO D, THAL L. Dynamic measurement scale development for clinical trials in targeted populations Controlled Clinical Trials. 19: S58-S58. DOI: 10.1016/S0197-2456(98)80153-0  0.431
1998 BERG J, THOMAS R, THAL L, SANO M. Measuring cognitive progression in Alzheimer's disease Controlled Clinical Trials. 19: S57-S58. DOI: 10.1016/S0197-2456(98)80152-9  0.432
1997 Gold M, Thal LJ. Physostigmine and Alzheimer's disease [4] (multiple letters) Neurology. 49: 642-643. PMID 9270628  0.326
1997 Mackell JA, Ferris SH, Mohs R, Schneider L, Galasko D, Whitehouse P, Schmitt F, Sano M, Thal LJ. Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S65-9. PMID 9236955  0.362
1997 Sano M, Mackell JA, Ponton M, Ferreira P, Wilson J, Pawluczyk S, Pfeiffer E, Thomas RG, Jin S, Schafer K, Schittini M, Grundman M, Ferris SH, Thal LJ. The Spanish Instrument Protocol: design and implementation of a study to evaluate treatment efficacy Instruments for Spanish-speaking patients with Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S57-64. PMID 9236954  0.323
1997 Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S51-6. PMID 9236953  0.408
1997 Koss E, Weiner M, Ernesto C, Cohen-Mansfield J, Ferris SH, Grundman M, Schafer K, Sano M, Thal LJ, Thomas R, Whitehouse PJ. Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S45-50. PMID 9236952 DOI: 10.1097/00002093-199700112-00007  0.375
1997 Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S13-21. PMID 9236948  0.332
1997 Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S1-12. PMID 9236947  0.37
1997 Crook R, Ellis R, Shanks M, Thal LJ, Perez-Tur J, Baker M, Hutton M, Haltia T, Hardy J, Galasko D. Early-onset Alzheimer's disease with a presenilin-1 mutation at the site corresponding to the Volga German presenilin-2 mutation. Annals of Neurology. 42: 124-8. PMID 9225696 DOI: 10.1002/Ana.410420121  0.508
1997 Olichney JM, Sabbagh MN, Hofstetter CR, Galasko D, Grundman M, Katzman R, Thal LJ. The impact of apolipoprotein E4 on cause of death in Alzheimer's disease. Neurology. 49: 76-81. PMID 9222173 DOI: 10.1212/Wnl.49.1.76  0.694
1997 Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 49: 56-61. PMID 9222170 DOI: 10.1212/Wnl.49.1.56  0.74
1997 Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology. 48: 1508-10. PMID 9191756 DOI: 10.1212/Wnl.48.6.1508  0.301
1997 Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, Galasko D, Thal LJ, Beal MF, Howell N, Parker WD. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 94: 4526-31. PMID 9114023 DOI: 10.1073/Pnas.94.9.4526  0.512
1997 Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. The New England Journal of Medicine. 336: 1216-22. PMID 9110909 DOI: 10.1056/Nejm199704243361704  0.409
1997 Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, Kang D, Chen X, Wiederholt W, Hansen L, Masliah E, Thal LJ, Katzman R, Xia Y, Saitoh T. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Annals of Neurology. 41: 277-81. PMID 9029080 DOI: 10.1002/Ana.410410222  0.735
1997 Corey-Bloom J, Sabbagh MN, Bondi MW, Hansen L, Alford MF, Masliah E, Thal LJ. Hippocampal sclerosis contributes to dementia in the elderly. Neurology. 48: 154-60. PMID 9008511 DOI: 10.1212/Wnl.48.1.154  0.633
1997 Winkler J, Ramirez GA, Kuhn HG, Peterson DA, Day-Lollini PA, Stewart GR, Tuszynski MH, Gage FH, Thal LJ. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Annals of Neurology. 41: 82-93. PMID 9005869 DOI: 10.1002/ana.410410114  0.328
1997 Thal LJ. Physostigmine and Alzheimer's disease Neurology. 49: 643-643. DOI: 10.1212/Wnl.49.2.643  0.396
1997 Mackell JA, Ferris SH, Mohs R, Schneider L, Galasko D, Whitehouse P, Schmitt F, Sano M, Thal LJ. Multicenter Evaluation of New Instruments for Alzheimerʼs Disease Clinical Trials Alzheimer Disease & Associated Disorders. 11: 65-69. DOI: 10.1097/00002093-199700112-00010  0.411
1997 Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ. The Severe Impairment Battery Alzheimer Disease & Associated Disorders. 11: 51-56. DOI: 10.1097/00002093-199700112-00008  0.431
1997 Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ. Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. Alzheimer Disease & Associated Disorders. 11: 13-21. DOI: 10.1097/00002093-199700112-00003  0.419
1997 Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ. A Multicenter Evaluation of New Treatment Efficacy Instruments for Alzheimerʼs Disease Clinical Trials Alzheimer Disease & Associated Disorders. 11: 1-12. DOI: 10.1097/00002093-199700112-00002  0.476
1997 Thal LJ. Development of the Alzheimer's disease cooperative study International Journal of Geriatric Psychopharmacology. 1: 6-9.  0.327
1996 Thal LJ. Cholinomimetic treatment of Alzheimer's disease. Progress in Brain Research. 109: 299-309. PMID 9009718 DOI: 10.1016/S0079-6123(08)62113-5  0.429
1996 Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, Bodenheimer S, Rossor M, Philpot M, Schor J, Goldberg A. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology. 47: 1389-95. PMID 8960716 DOI: 10.1212/Wnl.47.6.1389  0.402
1996 Peavy GM, Salmon DP, Rice VA, Galasko D, Samuel W, Taylor KI, Ernesto C, Butters N, Thal L. Neuropsychological assessment of severely demeted elderly: the severe cognitive impairment profile. Archives of Neurology. 53: 367-72. PMID 8929160 DOI: 10.1001/Archneur.1996.00550040107020  0.588
1996 Thal LJ. Potential prevention strategies for Alzheimer disease. Alzheimer Disease and Associated Disorders. 10: 6-8. PMID 8876780 DOI: 10.1097/00002093-199601031-00002  0.405
1996 Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M, Growdon J, Thal LJ. Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 10: 132-40. PMID 8876776 DOI: 10.1097/00002093-199601030-00004  0.484
1996 Salmon DP, Galasko D, Hansen LA, Masliah E, Butters N, Thal LJ, Katzman R. Neuropsychological deficits associated with diffuse Lewy body disease. Brain and Cognition. 31: 148-65. PMID 8811990 DOI: 10.1006/Brcg.1996.0039  0.717
1996 Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, Pettegrew JW, Pfeiffer E, Raskind MA, Sano M, Tuszynski MH, Woolson RF. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 47: 705-11. PMID 8797468 DOI: 10.1212/Wnl.47.3.705  0.455
1996 Peskind ER, Raskind MA, Wingerson D, Pascualy M, Thal LJ, Dobie DJ, Wilkinson CW. Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: effects of Alzheimer's disease and gender. Biological Psychiatry. 40: 61-8. PMID 8780856 DOI: 10.1016/0006-3223(95)00318-5  0.412
1996 Xia Y, Rohan de Silva HA, Rosi BL, Yamaoka LH, Rimmler JB, Pericak-Vance MA, Roses AD, Chen X, Masliah E, DeTeresa R, Iwai A, Sundsmo M, Thomas RG, Hofstetter CR, Gregory E, ... ... Thal LJ, et al. Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. Annals of Neurology. 40: 207-15. PMID 8773602 DOI: 10.1002/Ana.410400212  0.617
1996 Ellis RJ, Caligiuri M, Galasko D, Thal LJ. Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Alzheimer Disease and Associated Disorders. 10: 103-14. PMID 8727172 DOI: 10.1097/00002093-199601020-00008  0.638
1996 Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, Thal LJ. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology. 47: 190-6. PMID 8710076 DOI: 10.1212/Wnl.47.1.190  0.72
1996 Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology. 46: 1592-6. PMID 8649554 DOI: 10.1212/Wnl.46.6.1592  0.448
1996 Grundman M, Corey-Bloom J, Jernigan T, Archibald S, Thal LJ. Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy. Neurology. 46: 1585-91. PMID 8649553 DOI: 10.1212/Wnl.46.6.1585  0.588
1996 Thal LJ. Chapter 31 Neurotrophic factors Progress in Brain Research. 109: 327-330. DOI: 10.1016/S0079-6123(08)62115-9  0.356
1996 Schafer K, Thomas R, Galasko D, Morris JC, Whitehouse P, Bochenek J, Thal L. P63 Informed consent issues when including genetic testing in clinical trials Controlled Clinical Trials. 17: S130-S131. DOI: 10.1016/0197-2456(96)84683-6  0.444
1995 Bondi MW, Salmon DP, Monsch AU, Galasko D, Butters N, Klauber MR, Thal LJ, Saitoh T. Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology. 45: 2203-6. PMID 8848194 DOI: 10.1212/Wnl.45.12.2203  0.478
1995 Peskind ER, Wingerson D, Pascualy M, Thal L, Veith RC, Dorsa DM, Bodenheimer S, Raskind MA. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma. Biological Psychiatry. 38: 532-8. PMID 8562665 DOI: 10.1016/0006-3223(94)00377-F  0.368
1995 Katzman R, Galasko D, Saitoh T, Thal LJ, Hansen L. Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Brain and Cognition. 28: 259-65. PMID 8546853 DOI: 10.1006/Brcg.1995.1256  0.717
1995 Olichney JM, Galasko D, Corey-Bloom J, Thal LJ. The spectrum of diseases with diffuse Lewy bodies. Advances in Neurology. 65: 159-70. PMID 7872137  0.494
1995 Corey-Bloom J, Thal LJ, Galasko D, Folstein M, Drachman D, Raskind M, Lanska DJ. Diagnosis and evaluation of dementia. Neurology. 45: 211-8. PMID 7854514 DOI: 10.1212/Wnl.45.2.211  0.66
1995 Saitoh T, Xia Y, Chen X, Masliah E, Galasko D, Shults C, Thal LJ, Hansen LA, Katzman R. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Annals of Neurology. 37: 110-2. PMID 7818242 DOI: 10.1002/Ana.410370120  0.7
1995 Monsch AU, Bondi MW, Salmon DP, Butters N, Thal LJ, Hansen LA, Wiederholt WC, Cahn DA, Klauber MR. Clinical validity of the Mattis Dementia Rating Scale in detecting Dementia of the Alzheimer type. A double cross-validation and application to a community-dwelling sample. Archives of Neurology. 52: 899-904. PMID 7661728 DOI: 10.1001/Archneur.1995.00540330081018  0.382
1995 Olichney JM, Hofstetter CR, Galasko D, Thal LJ, Katzman R. Death certificate reporting of dementia and mortality in an Alzheimer's disease research center cohort. Journal of the American Geriatrics Society. 43: 890-3. PMID 7636097 DOI: 10.1111/J.1532-5415.1995.Tb05532.X  0.639
1995 Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman R, Thal LJ. Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Archives of Neurology. 52: 702-8. PMID 7619027 DOI: 10.1001/archneur.1995.00540310076019  0.561
1995 Chen X, Xia Y, Alford M, DeTeresa R, Hansen L, Klauber MR, Katzman R, Thal L, Masliah E, Saitoh T. The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Annals of Neurology. 38: 653-8. PMID 7574463 DOI: 10.1002/Ana.410380415  0.654
1995 Schafer K, Thal L, Bochenek J, Sano M, Grundman M, Woodbury P, Klauber M, Aisen P. P44 Implementation of multicenter clinical trials: The Alzheimer's Disease Cooperative Study protocol implementation manual Controlled Clinical Trials. 16: 97S. DOI: 10.1016/0197-2456(95)90524-9  0.374
1995 Davis KL, Yang RK, Davidson M, Mohs RC, Ryan TM, Schmeidler J, Knott PJ, Thal LJ, Gamzu ER. Alzheimer's disease: Tacrine and tacrine metabolite concentrations in plasma and cognitive change Drug Development Research. 34: 55-65. DOI: 10.1002/Ddr.430340109  0.376
1994 Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ. A validation study of the Dementia Questionnaire. Archives of Neurology. 51: 901-6. PMID 8080390 DOI: 10.1001/Archneur.1994.00540210073015  0.397
1994 Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, Hill LR, Lessin P, Thal LJ. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Archives of Neurology. 51: 888-95. PMID 8080388 DOI: 10.1001/archneur.1994.00540210060013  0.713
1994 Galasko D, Saitoh T, Xia Y, Thal LJ, Katzman R, Hill LR, Hansen L. The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. Neurology. 44: 1950-1. PMID 7936253 DOI: 10.1212/Wnl.44.10.1950  0.692
1994 Thal LJ. Future directions for research in Alzheimer's disease. Neurobiology of Aging. 15: S71-2. PMID 7700466 DOI: 10.1016/0197-4580(94)90174-0  0.395
1994 Thal L. Clinical Diversity in Late Onset Alzheimer's Disease (Maudsley Monographs 34) Neurology. 44: 587-587. DOI: 10.1212/WNL.44.3_Part_1.587-c  0.439
1993 Cutler NR, Sramek JJ, Levy R, Gracon SI, Lachs M, Meloff K, Davis KL, Thal LJ, Growdon JH. Tacrine in Alzheimer's disease [1] New England Journal of Medicine. 328: 808-810. PMID 8437603 DOI: 10.1056/NEJM199303183281114  0.331
1993 Corey-Bloom J, Galasko D, Hofstetter CR, Jackson JE, Thal LJ. Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia. Journal of the American Geriatrics Society. 41: 31-7. PMID 8418119 DOI: 10.1111/J.1532-5415.1993.Tb05944.X  0.704
1993 Galasko D, Abramson I, Corey-Bloom J, Thal LJ. Repeated exposure to the Mini-Mental State Examination and the Information-Memory-Concentration Test results in a practice effect in Alzheimer's disease. Neurology. 43: 1559-63. PMID 8351011 DOI: 10.1212/Wnl.43.8.1559  0.645
1993 O'Connor DT, Kailasam MT, Thal LJ. Cerebrospinal fluid chromogranin A is unchanged in Alzheimer dementia. Neurobiology of Aging. 14: 267-9. PMID 8321395 DOI: 10.1016/0197-4580(93)90011-Y  0.46
1993 Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ. Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature. 361: 260-3. PMID 7678698 DOI: 10.1038/361260a0  0.474
1992 Jeste DV, Wragg RE, Salmon DP, Harris MJ, Thal LJ. Cognitive deficits of patients with Alzheimer's disease with and without delusions. The American Journal of Psychiatry. 149: 184-9. PMID 1734737  0.389
1992 Monsch AU, Bondi MW, Butters N, Salmon DP, Katzman R, Thal LJ. Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type. Archives of Neurology. 49: 1253-8. PMID 1449404 DOI: 10.1001/Archneur.1992.00530360051017  0.574
1992 Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. The New England Journal of Medicine. 327: 1253-9. PMID 1406817 DOI: 10.1056/Nejm199210293271801  0.459
1992 Galasko D, Corey-Bloom J, Thal LJ. In reply Journal of the American Geriatrics Society. 40: 538. DOI: 10.1111/j.1532-5415.1992.tb02031.x  0.426
1991 Galasko D, Corey-Bloom J, Thal LJ. Monitoring progression in Alzheimer's disease. Journal of the American Geriatrics Society. 39: 932-41. PMID 1842209 DOI: 10.1111/J.1532-5415.1991.Tb04463.X  0.727
1990 Salmon DP, Thal LJ, Butters N, Heindel WC. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology. 40: 1225-30. PMID 2381530 DOI: 10.1212/WNL.40.8.1225  0.37
1990 Galasko D, Kwo-on-Yuen PF, Klauber MR, Thal LJ. Neurological findings in Alzheimer's disease and normal aging. Archives of Neurology. 47: 625-7. PMID 2346387 DOI: 10.1001/Archneur.1990.00530060033012  0.64
1990 Galasko D, Klauber MR, Hofstetter CR, Salmon DP, Lasker B, Thal LJ. The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease. Archives of Neurology. 47: 49-52. PMID 2294894 DOI: 10.1001/archneur.1990.00530010061020  0.574
1990 Thal LJ. THA, a putative drug in the treatment of Alzheimer's disease? Acta Neurologica Scandinavica. Supplementum. 129: 27-8. PMID 2220321 DOI: 10.1111/J.1600-0404.1990.Tb02600.X  0.379
1989 Masur DM, Fuld PA, Blau AD, Thal LJ, Levin HS, Aronson MK. Distinguishing normal and demented elderly with the selective reminding test. Journal of Clinical and Experimental Neuropsychology. 11: 615-30. PMID 2808653 DOI: 10.1080/01688638908400920  0.347
1989 Thal LJ, Salmon DP, Lasker B, Bower D, Klauber MR. The safety and lack of efficacy of vinpocetine in Alzheimer's disease. Journal of the American Geriatrics Society. 37: 515-20. PMID 2715559 DOI: 10.1111/J.1532-5415.1989.Tb05682.X  0.434
1989 Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. Journal of the American Geriatrics Society. 37: 42-8. PMID 2642499 DOI: 10.1111/J.1532-5415.1989.Tb01567.X  0.358
1989 Salmon DP, Kwo-on-Yuen PF, Heindel WC, Butters N, Thal LJ. Differentiation of Alzheimer's disease and Huntington's disease with the Dementia Rating Scale. Archives of Neurology. 46: 1204-8. PMID 2530966 DOI: 10.1001/archneur.1989.00520470060028  0.446
1988 Katzman R, Brown T, Thal LJ, Fuld PA, Aronson M, Butters N, Klauber MR, Wiederholt W, Pay M, Xiong RB. Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer's disease. Annals of Neurology. 24: 384-9. PMID 3228273 DOI: 10.1002/Ana.410240306  0.514
1988 Thal LJ. Drug treatment of alzheimer's disease Drug Development Research. 14: 189-189. DOI: 10.1002/ddr.430140305  0.376
1987 Thal LJ, Davies P. Detection of antigens in Alzheimer cerebrospinal fluid by monoclonal antibodies. Journal of the American Geriatrics Society. 35: 1047-50. PMID 3680836 DOI: 10.1111/j.1532-5415.1987.tb04919.x  0.404
1987 Thal LJ. Modern Approaches to the Dementias. Part I: Etiology and Pathophysiology Part II: Clinical and Therapeutic Aspects Neurology. 37: 1094-1094. DOI: 10.1212/Wnl.37.6.1094-B  0.318
1986 Thal LJ, Grundman M, Golden R. Alzheimer's disease: a correlational analysis of the Blessed Information-Memory-Concentration Test and the Mini-Mental State Exam. Neurology. 36: 262-4. PMID 3945395 DOI: 10.1212/WNL.36.2.262  0.335
1983 Schonfeld AR, Thal LJ, Horowitz SG, Katzman R. Heart conditioned medium elicits post-lesion muscarinic receptor recovery in vivo. Brain Research. 266: 271-8. PMID 6871663 DOI: 10.1016/0006-8993(83)90658-3  0.421
1981 Thal LJ, Rosen W, Sharpless NS, Crystal H. Choline chloride in Alzheimer disease. Annals of Neurology. 10: 580. PMID 7325608 DOI: 10.1002/ana.410100617  0.338
1981 Thal LJ, Rosen W, Sharpless NS, Crystal H. Choline chloride fails to improve cognition of Alzheimer's disease. Neurobiology of Aging. 2: 205-8. PMID 7312098  0.31
1981 Schonfeld AR, Thal LJ, Horowitz SG, Katzman R. Heart conditioned medium promotes central cholinergic regeneration in vivo. Brain Research. 229: 541-6. PMID 7306826 DOI: 10.1016/0006-8993(81)91019-2  0.423
1980 Thal LJ, Sharpless NS, Wolfson L, Katzman R. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. Annals of Neurology. 7: 570-6. PMID 6969054 DOI: 10.1002/ana.410070611  0.434
1980 Rosenfeld MR, Makman MH, Ahn HS, Thal LJ, Mishra RK, Katzman R. Selective influence of ergot alkaloids on cortical and striatal dopaminergic and sergotonergic receptors. Advances in Biochemical Psychopharmacology. 23: 83-93. PMID 6249092  0.406
1978 Thal LJ, Makman MH, Ahn HS, Mishra RK, Horowitz SG, Dvorkin B, Katzman R. 3H-Spiroperidol binding and dopamine-stimulated adenylate cyclase: evidence for multiple classes of receptors in primate brain regions. Life Sciences. 23: 629-33. PMID 99609 DOI: 10.1016/0024-3205(78)90044-9  0.411
Show low-probability matches.